Egetis Therapeutics AB (publ) (EGTX) - Total Liabilities
Based on the latest financial reports, Egetis Therapeutics AB (publ) (EGTX) has total liabilities worth Skr299.30 Million SEK (≈ $32.21 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Egetis Therapeutics AB (publ) - Total Liabilities Trend (2008–2024)
This chart illustrates how Egetis Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See how liquid is Egetis Therapeutics AB (publ)'s working capital to evaluate short-term liquidity relative to the company's equity base.
Egetis Therapeutics AB (publ) Competitors by Total Liabilities
The table below lists competitors of Egetis Therapeutics AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sociedad Comercial del Plata S.A.
BA:COME
|
Argentina | AR$223.33 Billion |
|
Yesco Holdings Co. Ltd
KO:015360
|
Korea | ₩912.27 Billion |
|
NexPoint Strategic Opportunities Fund
NYSE:NXDT
|
USA | $353.87 Million |
|
Metall Zug AG
SW:METN
|
Switzerland | CHF217.76 Million |
|
PetroVietnam General Services Corp
VN:PET
|
Vietnam | ₫10.80 Trillion |
|
Thirumalai Chemicals Limited
NSE:TIRUMALCHM
|
India | Rs28.12 Billion |
|
Síminn hf
IC:SIMINN
|
Iceland | Ikr25.09 Billion |
|
Central Omega Resources Tbk PT
JK:DKFT
|
Indonesia | Rp1.84 Trillion |
Liability Composition Analysis (2008–2024)
This chart breaks down Egetis Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Egetis Therapeutics AB (publ) (EGTX) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Egetis Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Egetis Therapeutics AB (publ) (2008–2024)
The table below shows the annual total liabilities of Egetis Therapeutics AB (publ) from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr299.40 Million ≈ $32.22 Million |
+39.52% |
| 2023-12-31 | Skr214.60 Million ≈ $23.09 Million |
+290.89% |
| 2022-12-31 | Skr54.90 Million ≈ $5.91 Million |
+30.00% |
| 2021-12-31 | Skr42.23 Million ≈ $4.54 Million |
-84.02% |
| 2020-12-31 | Skr264.34 Million ≈ $28.45 Million |
+949.09% |
| 2019-12-31 | Skr25.20 Million ≈ $2.71 Million |
+11.12% |
| 2018-12-31 | Skr22.68 Million ≈ $2.44 Million |
+94.52% |
| 2017-12-31 | Skr11.66 Million ≈ $1.25 Million |
+69.61% |
| 2016-12-31 | Skr6.87 Million ≈ $739.64K |
+58.77% |
| 2015-12-31 | Skr4.33 Million ≈ $465.87K |
-66.21% |
| 2014-12-31 | Skr12.81 Million ≈ $1.38 Million |
+215.75% |
| 2013-12-31 | Skr4.06 Million ≈ $436.60K |
-37.74% |
| 2012-12-31 | Skr6.52 Million ≈ $701.23K |
+67.36% |
| 2011-12-31 | Skr3.89 Million ≈ $418.98K |
+159.12% |
| 2010-12-31 | Skr1.50 Million ≈ $161.69K |
+448.39% |
| 2009-12-31 | Skr273.98K ≈ $29.48K |
-15.32% |
| 2008-12-31 | Skr323.55K ≈ $34.82K |
-- |
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate,… Read more